

BIOGRAPHY

Maria Fleseriu, MD, FACE is a Professor of Medicine and Neurological Surgery and Director of the Pituitary Center at Oregon Health and Science University in Portland, Oregon, USA and Past President of the Pituitary Society.

Dr. Fleseriu has a long-standing clinical and research interest in the pathophysiology and treatment of pituitary and adrenal disorders and has been global principal investigator in more than a dozen pituitary clinical trials. She is a frequent plenary guest speaker at national and international meetings and has authored over 200 manuscripts in prestigious journals, including guidelines and consensus papers for Cushing's, acromegaly and hypopituitarism as well as book chapters. Major focus on research now is individualized treatment of Cushing's and acromegaly with the goal of improving patients' outcomes.

Dr. Fleseriu has been awarded the title of "Doctor Honors Causa" by the University of Medicine and Pharmacy "Carol Davila" Bucharest, she serves on the Board of Directors for Pituitary Society as Program Chair and she is past chair of the Endocrine Society Guidelines Committee and the Hypopituitarism task force. She has also served on several committees for the Endocrine Society, Pituitary Society, European Society of Endocrinology and American Association of Clinical Endocrinology.

Dr. Fleseriu is Deputy Editor for *European Journal of Endocrinology*, Chief Editor of Pituitary Endocrinology for *Frontiers in Endocrinology*, Section Head for *Pituitary and Neuroendocrine F 1000*, Associate Editor for *Reviews in Endocrinology and Metabolism*, and a member of the editorial board of *Pituitary*. She has been involved in leadership positions of educational programs sponsored by the Endocrine Society, the Pituitary Society, and patient advocacy groups to teach physicians and patients about pituitary tumors and neuroendocrine disorders. She has served on multiple scientific advisory boards for biotechnology and pharmaceutical companies and participated in study design and has been global principal investigator for several Cushing's and acromegaly studies.

Publications/Creative Work:

Peer-reviewed

1. Gligor Maria, *Maria Grama Fleseriu* (1993) Gastrointestinal and Hepatic Injuries by NSAID. Timisoara Medical Journal, nr. 1-2, vol. XXXVIII.
2. *Maria Fleseriu* (1995) Study of Quality of Life After the Menopause – Influence of Hormonal Replacement Therapy. Sibiul Medical Journal, V, nr. 3.
3. *Maria Fleseriu* (1997) Hormonal Anomalies in Anorexia Nervosa. Acta Medica Transilvanica, vol 1, nr 2, 1, pp 75-79.
4. *Maria Fleseriu, I.Gh.Totoianu* (1998) Our Experience in Turner Syndrome - The Treatment with GH. Sibiul Medical Journal, VII, nr.2.
5. *Maria Fleseriu, I.Gh.Totoianu* (1998) Prevention of Male Infertility by the Precocious Screening for Varicocele and Ectopic Testes in Children and Teenagers. Acta Medica Transilvanica, nr 1, pp 22-25.
6. *Maria Fleseriu* (1998) Updates in the Pathophysiology and the Treatment of Hirsutism. Acta Medica Transilvanica, vol 1, nr. 1, pp 83-87.
7. *Maria Fleseriu, Eugen Tarsia* (1998) New challenges in HRT in Postmenopausal Women. Sibiul Medical Journal, nr. 4 Oct. – Dec.
8. Mihaela Stanciu, *Maria Fleseriu, Alina Gurghean, Cristina Pop, I.G. Totoianu* (1998) Correlation between Urinary Iodine and Endemic Goiter Prevalence in Sibiu. Medicine and Pharmacy Journal of Univ. of Medicine and Pharmacy Tg. Mures, Vol. 44, supl. 3.
9. *Maria Fleseriu, Mihaela Stanciu, Alina Gurghean, Cristina Pop, I.G. Totoianu* (1998) Endemic Goiter Prevalence on a prospective epidemiologic study in a Small Town of Sibiu Department (active detection), Medicine and Pharmacy Journal of University of Medicine and Pharmacy Tg. Mures, Vol. 44, supl. 3.
10. Simona Fica, *Maria Fleseriu, S.B. Catrina, C. Cucu, Adriana Ioachimescu, M. Coculescu* (1998) Functional Ovarian Disturbances in Hypercortisolism. Medicine and Pharmacy Journal of University of Medicine and Pharmacy Tg. Mures, Vol 44, supl 3.
11. Mihai Coculescu, *Maria Fleseriu et al* (1998) The Release of FSH, LH, TSH

Expressed in GH Producing Adenoma. Journal of Endocrinology, vol. 159 Supplements.

12. *Maria Fleseriu*, George Michel (1999) Efficacy in Diagnostic of Radiothallium Scintigraphy in Thyroid Nodules - longitudinal study on 300 cases in the Hospital of Luxembourg. Sibiul Medical Journal nr. 2 April-June, pp. 150 - 152.
13. *Maria Fleseriu*, Michael Lee, Amir Hamrahian et al (2006) Giant Invasive Pituitary Prolactinoma with Moderate Elevation of Serum Prolactin, the Significance of Hook Effect. J. Neurooncol. Aug; 79(1):41-3.
14. *Maria Fleseriu*, Mario Skugor, Elias Siraj (2006) Successful Treatment of Sulfonylurea-induced Prolonged Hypoglycemia. Endocrine Practice, Nov-Dec; 12(6): 635-40.
15. Mehmet K. Aktas, *Maria Fleseriu*, Robert J. Weil, Charles Faiman, Orlin T. Sergev, Sethu Reddy, Amir H. Hamrahian (2007) Graves' Disease Exacerbation After Pituitary Adenectomy for Cushing's Disease Resulting in an Adrenal Crisis. Endocrinologist. 17(4): 206-208, July/August.
16. *Maria Fleseriu*, Angelo Licata (2007) Failure of successful renal transplant to produce appropriate levels of 1, 25 vitamin D. Osteoporosis Int. Mar; 18(3): 363-8. Epub 2006 Oct 24.
17. *Maria Fleseriu*, Swee H. The, Chris G. Yedinak, Clifford Deveney, William Ludlam, Brett C. Sheppard (2009) Cushing's Syndrome May be Under Appreciated in Patients Seeking Bariatric Surgery: A Plea for Screening. Surg. Obes. Relat. Dis. Jan-Feb; 5(1): 116-9.
18. *Maria Fleseriu*, Christine Yedinak, Caitlin Campbell, Johnny B. Delashaw (2009) Significant headache improvement after transsphenoidal surgery in patients with small sellar lesions. J Neurosurg. Feb; 110(2): 354-8.
19. Kristine Dziurzynski, Johnny B. Delashaw, Jr., S. Humayun Gultekin, *Maria Fleseriu* (2009) Diabetes insipidus, panhypopituitarism, and severe mental status deterioration in a patient with chordoid glioma: case report and literature review. Endocr. Pract. May-Jun; 15(3): 240-5.
20. Dillard T, Yedinak CG, Alumkal J, *Maria Fleseriu* (2010) Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events

across a spectrum of cancer subtypes. *Pituitary*; 13(1): 29-38.

21. *Maria Fleseriu*, DL Loriaux (2009) Relative Adrenal Insufficiency in Critical Illness. *Endocr Pract.* Jul 20:1-27.
22. *Maria Fleseriu*, Marika Gassner, Christine Yedinak, Liana Chicea, Johnny B. Delashaw, D. Lynn Loriaux (2010) Normal hypothalamic-pituitary-adrenal axis by high-dose Cortrosyn stimulation testing in patients with abnormal low dose Cortrosyn stimulation-a retrospective study. *Endocr. Pract.* Jan-Feb; 16(1): 64-70.
23. Raphael El Youssef, *Maria Fleseriu*, Brett C Sheppard (2010) Adrenal and Pancreatic Presentation of Subdiaphragmatic Retroperitoneal Bronchogenic Cysts. *Arch. Surg.* Mar; 145(3): 302-4.
24. William Chapin, Christine G. Yedinak, Johnny B. Delashaw, *Maria Fleseriu* (2010) Cabergoline induced cerebral spinal fluid leak in a patient with a large prolactinoma and MEN1 A Case Report and Review of the Literature. *The Endocrinologist*, vol 20, Nr 4, July/August.
25. *Maria Fleseriu*, Johnny Delashaw, David Cook (2010) Current medical therapy and new drugs on the horizon for the treatment of acromegaly. *Neurosurgical focus*, vol 29, Nr.4 :Oct.
26. Troy Dillard, S.Hume Gultelkin, Edward A Neuwelt, Johnny B. Delashaw, *Maria Fleseriu* (2011) Temozolomide for corticotroph adenomas refractory to surgery and radiation. *Pituitary.* Mar; 14(1): 80-91.
27. *Maria Fleseriu* (2011), [Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review](#), *Pituitary.* Jun; 14(2): 184-93. Review.
28. Jessica A. Brzana, Chris G. Yedinak, Johnny B. Delashaw, Hume S Gultelkin, David Cook, *Maria Fleseriu* (2012), Discordant results of GH and IGF1 results in patients with acromegaly after surgery, naïve to medical therapy and radiotherapy-what should we follow-GH or IGF1?, *Pituitary*, Dec;15(4):562-70.
29. *Maria Fleseriu*, Stephan Petersenn (2012), Update in Medical Management for Cushing's disease, what is the future? *Pituitary*, Sep; 15(3): 330-41.
30. *Maria Fleseriu*, Beverly Biller, Jay Findling, Mark Molitch, David Schteingart, Coleman Gross (2012) Mifepristone, a Glucocorticoid Receptor Antagonist produces

clinical and metabolic benefits in patients with refractory Cushing's syndrome: results from the SEISMIC study, *J Clin Endocrinol Metab.* 2012 97: 2039-2049.

31. Subbarayan S, *Maria Fleseriu*, Gordon M, Brzana J, Kennedy L, Faiman C, Hatipoglu B, Prayson RA, Delashaw JB, Weil RJ, Hamrahian AH (2012), Serum IGF-1 in the diagnosis of acromegaly and the profile of patients with elevated IGF-1 but normal glucose-suppressed growth hormone, *Endocr Pract.* Jul 11:1-24.
32. *Maria Fleseriu* (2012), Medical management of persistent and recurrent Cushing's disease after failed surgery, *Neurosurgery Clinics of North America, Management of Pituitary Tumors*, 23:4, Oct; 23(4): 653-68.
33. Jessica Brzana, Chris Yedinak, Sakir Gultekin, Johnny Delashaw, *Maria Fleseriu* (2013), Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response, *Pituitary*, Dec; 15(4): 562-70.
34. Nadia Hameed, Jessica Brzana, Chris Yedinak, Sakir Gultekin, Johnny Delashaw, *Maria Fleseriu* (2013), Remission rate after transsphenoidal surgery in patients with pathologically confirmed Cushing's disease, the role of cortisol, ACTH assessment and immediate reoperation: a large single center experience, *Pituitary*, 2013 Dec;16(4):452-8.
35. *Maria Fleseriu*, Mark Molitch, Coleman Gross, David Schteingart, Brooks Vaughan, Beverly MK Biller (2013), A new therapeutic approach in the medical treatment of Cushing's syndrome: glucocorticoid receptor blockade with Mifepristone, *Endocrine Practice*, Volume 19, Number 2 / March-April 2013, 312-327.
36. *Maria Fleseriu*, Stephan Petersenn (2013), "New Avenues in the Medical Treatment of Cushing's Disease – Corticotroph Tumor Targeted Therapy", *Journal of Neurooncology*, 2013 Aug; 114(1):1-11.
37. Jessica Brzana, Chris Yedinak, Nadia Hameed, *Maria Fleseriu* (2013), FRAX and vertebral fractures in acromegaly; the full story? *Clinical Endocrinology* Apr; 80(4):614-6.
38. X Bertagna, R Pivonello, *M Fleseriu*, YZhang, P Robinson, ATaylor, Watson, M. Maldonado, A Hamrahian, M Boscaro, BMK Biller (2013), Patients with Cushing's disease achieve normal urinary cortisol with LCI699, a potent 11 β -hydroxylase

inhibitor: results from a multicenter, proof-of-concept study, *J Clin Endocrinol Metab*, Apr; 99(4): 1375-83.

39. M Boscaro, J Bertherat, J Findling, *Fleseriu M*, Atkinson B, Petersenn S, Schopohl J, Snyder P, Sen K, Trovato A, Hu K, Maldonado M, Biller BMK (2013), Extended treatment of Cushing's disease with the somatostatin analog Pasireotide: results from a multicenter, Phase II extension, *Pituitary*, Aug; 17(4): 320-6.
40. Hai Sun, Jessica Brzana, Chris Yedinak, Sakir Gultekin, Johnny Delashaw, *Maria Fleseriu* (2013), Factors associated with biochemical remission after microscopic transsphenoidal surgery for acromegaly, *Journal of Neurosurgery, Skull Base* 2014 Feb; 75(1): 47-52.
41. Lucio Vilar, *Maria Fleseriu*, Naves LA, Albuquerque JL, Gadelha PS, dos Santos Faria M, Nascimento GC, Montenegro RM Jr, Montenegro RM (2013), Can we predict long-term remission after somatostatin analog withdrawal in patients with acromegaly? Results from a multicenter prospective trial, *Endocrine*, Aug; 46(3): 577-84.
42. Chris Yedinak, Jessica Brzana, *Maria Fleseriu* (2013), Monitoring Patient Improvement Parameters Following Medical Treatment of Cushing's Disease, *International Journal Of Endocrinology, Case Rep Endocrinol*; 735489.
43. Schroeder JL, Spiotta AM, *Maria Fleseriu*, Prayson RA, Hamrahian AH, Weil RJ. (2014), Absence of immunostaining for growth hormone in a subset of patients with acromegaly, *Pituitary*, Apr; 17(2): 103-8.
44. Chris Yedinak, *Maria Fleseriu* (2014), Self-Perception of Cognitive Function among Patients with Active Acromegaly, Controlled Acromegaly and Non-Functional Pituitary Adenoma, *Endocrine*, Aug; 46(3): 585-93.
45. Lucio Vilar, *Maria Fleseriu*, Marcello Bronstein (2014), Challenges and pitfalls in the diagnosis of hyperprolactinemia, *Arq Bras Endocrinol Metab*, 58:9-22.
46. J Brzana, C Yedinak, N Hameed, S McCartney, *Maria Fleseriu* (2014), Polycystic ovary syndrome (PCOS) and Cushing's syndrome (CS) – a clinical conundrum, *European Journal of Obstetrics & Gynecology and Reproductive Biology*, Apr; 175:145-8.
47. Colao A, Bronstein M, Freda P, Gu F, Shen C-C, Gadelha M, Mercado M, *Fleseriu*

- M, Hermosillo Reséndiz K, Ruffin M, Chen Y, and Sheppard M (2014), Efficacy and safety of pasireotide LAR versus octreotide LAR in patients with acromegaly, a randomized, double blind, multicenter, phase III study, *J Clin Endocrinol Metab*, Mar; 99(3): 791-9.
48. *Maria Fleseriu* (2014), Novel treatments for acromegaly, *Discovery Medicine*, 17(96): 329-338.
49. Daniel Cuevas- Ramos, *Maria Fleseriu* (2014), Treatment of Cushing's disease, a mechanistic update, *Journal of Endocrinology*, 2014 Nov;223(2):R19-R39.
50. S. Melmed, D.L. Kleinberg, V.S. Bonert, *M Fleseriu* (2014), Acromegaly, assessing the disorder and navigating therapeutic options for treatment, *Endocr Pract*. Oct 1;20(0):7-17.
51. *M Fleseriu*, J Findling, C Koch, M Buchfelder, S Shaffer, C Gross (2014), Changes in corticotroph tumor size and plasma ACTH levels in Cushing's disease patients during long-term treatment with the glucocorticoid antagonist mifepristone, *J Clin Endocrinol Metab*, Oct; 99(10):3718-27
52. M Gadelha, MD Bronstein, T Brue, M Coculescu, *M Fleseriu*, M Guitelman, V Pronin, G Raverot, I Shimon, K Kodama Lievre, J Fleck, M Aout, AM Pedroncelli, Colao A (2014), Superiority of pasireotide versus octreotide or lanreotide in patients with inadequately controlled acromegaly, *Lancet Diabetes & Endocrinology*, Nov;2(11):875-84
53. Chris G. Yedinak, Shirley McCartney, Troy H. Dillard, Kevin S. Wei, *Maria Fleseriu* (2014), Reversible cabergoline-associated cardiac valvulopathy post drug discontinuation, *F1000 research*, 3:171.
54. H. Sun, A. Ozpinar, C. Yedinak, J.B. Delashaw, A. Dogan, *M. Fleseriu* (2015), Preoperative lateralization modalities for Cushing's disease: Is magnetic resonance imaging or cavernous sinus sampling more predictive of intraoperative findings? , *Journal of Neurosurgery, Skull Base, J Neurol Surg B*; 76(03): 218-224
55. D Mo, *M Fleseriu*, R Qi, R Bouillon, C. Child, Dana S Hardin (2015), Fracture Risk in Adult Patients on Growth Hormone (GH) Replacement for Growth Hormone Deficiency (GHD): a Surveillance Database Analysis, *Lancet Diabetes and Endocrinology*. May;3(5):331-8.

56. B Javorski, T Carroll, R Salvatori, N Tritos, A Heaney, *M Fleseriu*, B Biller, J Findling (2015), Cushing's Syndrome in Patients who had Bariatric Surgery: A Multicenter Case Series, *Obes Surg.* Dec;25(12):2306-13
57. Yedinak, N Hameed, M. Gassner, J Brzana, *Maria Fleseriu* (2015), Recovery rate of adrenal function after surgery in patients with acromegaly is higher than in those with non-functioning pituitary tumors—a large single center study, *Pituitary.* Oct;18(5):701-9
58. *Maria Fleseriu*, Stephan Petersenn (2015) Adrenal steroidogenesis inhibitors and glucocorticoid receptor blockers in the treatment of Cushing's disease, *Pituitary, Special Issue on Cushing's Disease*; 18(2):245-52
59. Stephan Petersenn *Maria Fleseriu*, (2015) ACTH neuromodulators in the treatment of Cushing's disease, *Pituitary, Special Issue on Cushing's Disease*: 18(2):238-44.
60. Daniel Cuevas- Ramos, *Maria Fleseriu* (2014), "Somatostatin receptor ligands and resistance to treatment in pituitary adenomas", *Journal of Molecular Endocrinology*, Jun; 52(3): R223-R240.
61. *M Fleseriu*, A. Hoffman, L. Katznelson (2015), Preoperative medical therapy in acromegaly-AACE disease state review, *Endocrine Practice*, Jun;21(6):668-73.
62. Shimon I, Jallad RS, *Fleseriu M*, Yedinak CG, Greenman Y, Bronstein MD. Giant Growth Hormone-secreting Pituitary Adenomas: Management of Rare and Aggressive Pituitary Tumors (2015). *European Journal of Endocrinology* 2015 Jun;172(6):707-13.
63. *Fleseriu M*, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BMK, Bertagna X (2015), Efficacy and safety of the potent oral 11 β -hydroxylase inhibitor osilodrostat (LCI699) in patients with Cushing's disease: a 22-week, prospective, multicenter, open-label, Phase II study, *Pituitary*, Apr;19(2):138-48
64. Schmid HA, Brue T, Colao A, Gadelha MR, Shimon I, Kapur K, Pedroncelli AM, *Fleseriu M.* (2016), Effect of pasireotide on glucose and growth hormone related biomarkers in patients with inadequately controlled acromegaly, *Endocrine.* Jul;53(1):210-9
65. Findling JW, *Fleseriu M*, Newell-Price J, Petersenn S, Pivonello R, Kandra A,

- Pedroncelli AM, Biller BMK (2016), Late-night salivary cortisol may be a valuable tool for assessing treatment response in patients with Cushing's disease: results from a 12-month, randomized Phase III study of pasireotide, *Endocrine*, Nov;54(2):516-523
66. Bronstein MD, *Fleseriu M*, Neggers S, Colao A, Sheppard M, Gu F, Shen CC, Gadelha M, Farrall AJ, Hermosillo Reséndiz K, Ruffin M, Chen Y, Freda P (2016), Switching Patients from Octreotide LAR to Pasireotide LAR Improves Biochemical Control: Crossover Extension to a Double-Blind, Multicenter, Randomized, Phase III Study, *BMC Endocr Disord*. Apr 2;16:16. doi: 10.1186/s12902-016-0096-8.
67. *M Fleseriu*, A. Hamrahian, D. Kelly, A. Hoffman, L. Katznelson (2016), Diagnosis of recurrence in Cushing's disease -AACE disease state review, *Endocrine Practice*, Dec;22(12):1436-1448
68. Yedinak C, Cetas I, Ozpinar A, McCartney S, Dogan A, *M Fleseriu* (2016), Dopamine agonist therapy induces significant recovery of HPA axis function in prolactinomas independent of tumor size: a large single center experience, *Endocrine*, Oct;54(1):191-197
69. *Fleseriu M*, Bodach ME, Tumialan LM, Bonert V, Oyesiku NM, Patil CG, Litvack Z, Aghi MK, Zada G (2016), "Congress of neurological surgeons Systematic Review and Evidence-Based Guideline for Pre-Treatment Endocrine evaluation of patients with Non-functioning Pituitary Adenoma", *Neurosurgery*. Oct;79(4):E527-9
70. Ziu M, Dunn IF, Hess C, *Fleseriu M*, Bodach ME, Tumialan LM, Oyesiku NM, Patel KS, Wang R, Carter BS, Chen JY, Chen CC, Patil CG, Litvack Z, Zada G, Aghi MK. (2016), Congress of Neurological Surgeons Systematic Review and Evidence-Based Guideline on Post-Treatment Follow-up Evaluation of Patients with Non-Functioning Pituitary Adenoma" Oct;79(4):E541-3
71. Aghi MK, Chen CC, *Fleseriu M*, Newman SA, Lucas JW, Kuo JS, Barkhoudarian G, Farrell CJ, Sheehan J, Ziu M, Dunn IF (2016), "Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients with Non-Functioning Pituitary Adenomas: Executive Summary", *Neurosurgery*, Oct;79(4):521-3
72. *Fleseriu M*, Castinetti F (2016), Updates on the role of adrenal steroidogenesis

inhibitors, *Pituitary*. Dec;19(6):643-653

73. Maria *Fleseriu*, Ibrahim A. Hashim, Niki Karavitaki, Shlomo Melmed, M. Hassan Murad, Roberto Salvatori, Mary H. Samuels (2016), Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline, *J Clin Endocrinol Metab*, Nov;101(11):3888-3921
74. DS Lim, *M.Fleseriu* (2017), The role of combination medical therapy in acromegaly, *Pituitary*, Feb;20(1):136-148
75. *Fleseriu M*, Rusch E, Geer EB, Access Study Investigators (2017), Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study, *Endocrine*, Jan; 55(1):247-255
76. Hamrahian H, *Fleseriu M* (2017), Evaluation and Management of Adrenal Insufficiency in Critically Ill Patients-Disease State Review, *Endocrine Practice*, Jun;23(6):716-725
77. Yedinak CG, Hopkins S, Williams J, Ibrahim A, Cetas JS and *Fleseriu M* (2017) Medical Therapy with Pasireotide in Recurrent Cushing's Disease: Experience of Patients Treated for At Least 1 Year at a Single Center.*Front. Endocrinol.* 8:35.oi: 10.3389/fendo.2017
78. Langlois F, McCartney S, *Fleseriu M* (2017), Recent progress in the medical therapy of pituitary tumors, *Endocrinol Metab.* Jun;32(2):162-170
79. Bridges K, Li R, *Fleseriu M*, Cetas J. (2017), Candida meningitis after transphenoidal surgery: a single institution case-series and literature review. *World Neurosurgery*, WNS-17-1044.
80. F Langlois, DS Lim, C.Yedinak, J S. Cetas, S. McCartney, A. Dogan, *M. Fleseriu* (2018), Predictors of silent corticotroph adenoma recurrence; a large retrospective single center study and systematic literature review, *Pituitary* Feb;21(1):32-40. doi: 10.1007/s11102-017-0844-4.
81. F Langlois, E Varlamov, DS Lim, C.Yedinak, J S. Cetas, S. McCartney, A. Dogan, *M. Fleseriu* (2017), Clinical profile of silent growth hormone pituitary adenomas; higher recurrence rate compared to silent gonadotroph pituitary tumors, a large single

center experience, *Endocrine*, Dec;58(3):528-534

82. Gheorghiu ML, *Fleseriu M* (2017), *Clinical review/Extensive clinical experience*, Stereotactic Radiation Therapy in Pituitary Adenomas, is it Better than Conventional Radiation Therapy, *Acta Endo (Buc)* 13: 476-490 doi: 10.4183/aeb.2017.476
83. *Fleseriu M* (2018), Recombinant growth hormone treatment, osteoporosis and fractures, more complicated than it seems! *Endocrine*. Mar; 59(3):463-465
84. Langlois F, Woltjer R, Cetas JS, *Fleseriu M* (2018), Silent somatotroph pituitary adenomas: an update, *Pituitary*. Apr; 21(2):194-202
85. Langlois F, Chu J, *Fleseriu M* (2018), Pituitary Directed Therapies for Cushing's disease, Pituitary-Directed Therapies for Cushing's Disease, *Front Endocrinol (Lausanne)*. May 1; 9:164. doi: 10.3389/fendo.2018.00164
86. Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, *Fleseriu M* (2018), Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. *Pituitary*. Jun 23, Jun 23. doi: 10.1007/s11102-018-0898-
87. Nachtigall LB, Karavitaki N, Kiseljak-Vassiliades K, Ghalib L, Fukuoka H, Syro LV, Kelly D, *Fleseriu M*. (2018), Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey, *Pituitary*. Nov 19. doi: 10.1007/s11102-018-0924-0.
88. Ioachimescu AG, *Fleseriu M*, Hoffman AR, Vaughan Iii TB, Katznelson L(2018), Psychological effects of Dopamine Agonist Treatment in Patients with Hyperprolactinemia and Prolactin Secreting Adenomas., *Eur J Endocrinol*. Oct 1. pii: EJE-18-0682.R1. doi: 10.1530/EJE-18-0682.
89. Zahr R, *Fleseriu M*., Updates in Diagnosis and Treatment of Acromegaly (2018), *Eur Endocrinol*. Sep;14(2):57-61. doi: 10.17925/EE.2018.14.2.57.
90. Langlois F, Manea A, Lim DST, McCartney S, Yedinak CG, Cetas JS, *Fleseriu M* (2019), High prevalence of adrenal insufficiency at diagnosis and headache recovery in surgically resected Rathke's cleft cysts-a large retrospective single center study *Endocrine*. Mar;63(3):463-469
91. Wagner J, Langlois F, Lim DST, McCartney S, *Fleseriu M* (2019), Hypercoagulability and Risk of Venous Thromboembolic Events in Endogenous

Cushing's Syndrome: A Systematic Meta-Analysis. *Front Endocrinol (Lausanne)*. Jan 28; 9:805.

92. Gadelha MR, Kasuki L, Lim DS, *Fleseriu M* (2019), Systemic complications of acromegaly and the impact of the current treatment landscape: an update, *Endocr Rev*. Feb 1;40(1):268-332.
93. A Vaidya, A Hamrahian, I Bancos, *M Fleseriu*, HK Ghayee on behalf of the AACE Pituitary, Gonad, Adrenal, and Neuroendocrine Disease State Network (2019), The evaluation of incidentally discovered adrenal masses, *Endocrine Practice*, Feb;25(2):178-192
94. E Varlamov, J M Hinojosa-Amaya, M Stack and *M Fleseriu* (2019), Diagnostic utility of Ga-68-somatostatin receptor PET/CT in ectopic ACTH-secreting tumors: a systematic literature review and single center clinical experience, *Pituitary*, Oct;22(5):445-455
95. Snyders T, Chakos D, Swami U, Latour E, Chen Y, *Fleseriu M*, Milhem M, Zakharia Y, Zahr R (2019), Ipilimumab-induced hypophysitis, a single academic center experience, *Pituitary*. Jul 20. doi: 10.1007/s11102-019-00978-4.
96. F J Guarda, J Findling, K C J Yuen, *M Fleseriu*, L B Nachtigall (2019), Mifepristone Increases Thyroid Hormone Requirements in Patients with Central Hypothyroidism - A Multicenter Study, *Journal of the Endocrine Society*, doi.org/10.1210/js.2019-00188
97. *M Fleseriu*, C Iweha, L Salgado, T.L Mazzuco, F Campigotto, R Maamari, P Limumpornpetch (2019) Safety and Efficacy of Subcutaneous Pasireotide in Patients with Cushing's Disease: Results From an Open-Label, Multicenter, Single-Arm, Multinational, Expanded-Access Study, *Front. Endocrinol* doi.org /10.3389 /fendo 2019.00436
98. *Fleseriu M*, Petersenn S, Biller BMK, Kadioglu P, De Block C, T'Sjoen G, Vantyghem MC, Tauchmanova L, Wojna J, Roughton M, Lacroix A, Newell-Price J (2019)., Long-term efficacy and safety of once-monthly pasireotide in Cushing's disease: A Phase III extension study, *Clin Endocrinol (Oxf)*. doi: 10.1111/cen.14081
99. *Fleseriu M*, Pivonello R, Elenkova A, et al (2019), Efficacy and safety of levoketoconazole in the treatment of endogenous Cushing's syndrome (SONICS): a

phase 3, multicentre, open-label, single-arm trial. *The Lancet Diabetes & Endocrinology* 7(11):855-865

100. *Fleseriu M*, Fogelfeld L, Gordon MB, Sisco J, Colwell HH, Ludlam WH, Haviv A, Mathias SD (2019), Development of a Novel Patient-Reported Measure for Acromegaly: The ACRO-TSQ, *Pituitary*, Dec 22(6):581-593.
101. Ho KKY, *Fleseriu M*, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, Melmed S (2019), “A tale of pituitary adenomas and neuroendocrine tumors, to NET or not to NET, a Pituitary Society Position Statement, *Pituitary*, Dec;22(6):569-573
102. Hinojosa-Amaya JM, Varlamov E, McCartney S, *Fleseriu M* (2019), Hypercortisolemia recurrence in Cushing’s disease; a diagnostic challenge, *Front. Endocrinol.* 10.3389/ fendo.2019.00740
103. Giustina A, Barkan A, Beckers A, Biermasz N, Biller BMK, Boguszewski C, Bolanowski M, Bonert V, Bronstein M, Casanueva FF, Clemmons D, Colao A, Ferone D, *Fleseriu M*, Frara S, Gadelha M, Ghigo E, Gurnell M, Heaney A, Ho K, Ioachimescu A, Katznelson L, Kelestimur F, Kopchick J, Krsek M, Lamberts S, Losa M, Luger A, Maffei, Marazuela M, Mazziotti G, Mercado M, Mortini P, Neggers S, Pereira AM, Petersenn S, Puig-Doming M, Salvatori R, Shimon I, Strasburger C, Tsagarakis S, van der Lely AJ, Wass J, Zatelli MC, Melmed S (2020), A consensus on the diagnosis and treatment of acromegaly complications; An update, *Journal of Endocrinology and Metabolism*, October
104. Chiloiro S, Giampietro A, Frara S, Bima C, Donfrancesco F, *Fleseriu CM*, Pontecorvi A, Giustina A, *Fleseriu M*, De Marinis L, Bianchi A (2020), Effects of Pegvisomant and Pasireotide LAR on incidence of vertebral fractures in patients with acromegaly resistant to treatment with First-Line Somatostatin Receptor Ligands, *Journal of Clinical Endocrinology and Metabolism*, Mar 1;105(3)
105. Newell-Price J, Pivonello R, Tabarin A, *Fleseriu M*, Witek P, Gadelha MR, Petersenn S, Tauchmanova L, Ravichandran S, Gupta P, Lacroix A, Biller B (2020), Use of late-night salivary cortisol to monitor response to medical treatment in Cushing's disease., *Eur J Endocrinol.* Feb;182(2):207-217
106. G Vila, *M Fleseriu*, Fertility and pregnancy in women with hypopituitarism: a

systematic literature review, *The Journal of Clinical Endocrinology & Metabolism* (2020), Mar 1;105(3)

107. MG Suarez, M Stack, JM Hinojosa, M Mitchell, EV Varlamov, CG Yedinak, J Cetas, *M Fleseriu* (2020), Hypercoagulability in Cushing's syndrome, prevalence of thrombotic events; a large single-center retrospective study, *Journal of the Endocrine Society*, bvz033, doi.org/10.1210/jendso/bvz033
108. Ho KKY, *Fleseriu M*, Wass J, van der Lely A, Barkan A, Giustina A, Casanueva FF, Heaney AP, Biermasz N, Strasburger C, Melmed S (2020), "The tale in evolution: clarity, consistency and consultation, not contradiction and confusion", *Pituitary*, January
109. Ambrosio MR, Gagliardi I, Chiloiro S, Ferreira AG, Bondanelli M, Giampietro A, Bianchi A, Marinis L, *Fleseriu M*, Zatelli MC (2020), Acromegaly in the elderly patients, *Endocrine*. Feb 14. doi: 10.1007/s12020-020-02206-7
110. Colao AAL, Bronstein MD, Brue T, De Marinis L, *Fleseriu M*, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III (PAOLA) study, *Eur J Endocrinol*, Jun;182(6):583
111. M Irwig, *M Fleseriu*, J Jonklaas, NA. Tritos, KCJ Yuen, R Correa, G Elhomsy, V Garla, S Jasim, K Soe, S E. Baldeweg, C L Boguszewski, I Bancos (2020) Off-label Use and Misuse of Testosterone, Growth Hormone, Thyroid Hormone, and Adrenal Supplements: Risks and Costs of a Growing Problem, an Association of Clinical Endocrinologists position statement, *Endocrine Practice*, March, Vol. 26, No. 3, pp. 340-353.
112. *Fleseriu M*, Fogelfeld L, Gordon MB, Sisco J, Crosby RD, Ludlam WH, Haviv A, Mathias SD (2020). An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies *Pituitary*. Mar 27. doi: 10.1007/s11102-020-01038-y
113. *Fleseriu M*, Karavitaki N, Dekkers OM (2020). Endocrinology in the time of COVID-19: Management of pituitary tumours, *Eur J Endocrinol.*; EJE-20-0473. doi:10.1530/EJE-20-0473

- 114.** *Fleseriu M, Buchfelder M, Cetas JS, et al (2020). Pituitary society guidance: pituitary disease management and patient care recommendations during the COVID-19 pandemic-an international perspective. Pituitary. 2020;23(4):327-337. doi:10.1007/s11102-020-01059-7*
- 115.** *Pivonello R, Fleseriu M, Newell-Price J, et al (2020). Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a doubleblind, randomised withdrawal phase [published online ahead of print, 2020 Jul 27]. Lancet Diabetes Endocrinol.;S2213-8587(20)30240-0. doi:10.1016/S2213-8587(20)30240*
- 116.** *Varlamov EV, Wood MD, Netto JP, Thiessen J, Kim J, Lim DST, Yedinak CG, Banskota S, Cetas JS, Fleseriu M (2020) Cystic appearance on magnetic resonance imaging in bihormonal growth hormone and prolactin tumors in acromegaly Dec;23(6):672-680. doi: 10.1007/s11102-020-01075-7*
- 117.** *Samson SL, Nachtigall LB, Fleseriu M, et al. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide (2020). J Clin Endocrinol Metab. ; Oct 1;105(10):e3785-97. doi: 10.1210/clinem/dgaa526*
- 118.** *Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S (2021). A Pituitary Society update to acromegaly management guidelines. Pituitary Feb;24(1):1-13. doi: 10.1007/s11102-020-01091-7*
- 119.** *Cooper O, Bonert VS, Rudnick J, Pressman BD, Lo J, Salvatori R, Yuen K, Fleseriu M, Melmed S (2021). EGFR/ErbB2 targeting lapatinib therapy for aggressive prolactinomas. J Clin Endocrinol Metab. Jan 23;106(2):e917-e925. doi: 10.1210/clinem/dgaa805.*
- 120.** *Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Angelini F, Lauretti L, Gessi M, Anile C, Rindi G, Giustina A, Fleseriu M, Pontecorvi A, De Marinis L, Bianchi A (2021). Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: Clinical effectiveness and predictors of response. Eur J Endocrinol. Feb;184(2):217-229. doi: 10.1530/EJE-20-0767.*
- 121.** *Geer EB, Salvatori R, Elenkova A, Fleseriu M, Pivonello R, Witek P, Feelders RA,*

- Bex M, Borresen SW, Puglisi S, Biller BMK, Cohen F, Giraldi FP (2021). Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing's syndrome. *Pituitary*. Feb;24(1):104-115. doi: 10.1007/s11102-020-01103-6ss
- 122.** M R Gadelha, F Gu, M D Bronstein, T C Brue, *M Fleseriu*, I Shimon, A J van der Lely, S Ravichandran, Albert Kandra, Alberto M Pedroncelli, Annamaria A Colao (2020), Risk factors and management of pasireotide-associated hyperglycemia in acromegaly, *Endocrine Connections*, 12. 9:12,1178–1190
- 123.** Pivonello R, Elenkova A, *Fleseriu M*, Feelders RA, Witek P, Greenman Y, Geer EB, Perotti P, Saiegh L, Cohen F and Arnaldi G (2021) Levoketoconazole in the Treatment of Patients With Cushing's Syndrome and Diabetes Mellitus: Phase 3 SONICS Results. *Front. Endocrinol.* 12:595894. doi: 10.3389/fendo.2021.595894
- 124.** Giustina A, Legg E, Cesana BM, Frara S, Mortini P, *Fleseriu M* (2021) Results from ACROCOVID: an international survey on the care of acromegaly during the COVID-19 era. *Endocrine*. Feb;71(2):273-280. doi: 10.1007/s12020-020-02565-1.
- 125.** Varlamov EV, Langlois F, Vila G, *Fleseriu M* (2021). Cardiovascular risk assessment, thromboembolism and infection prevention in Cushing's syndrome - a practical approach. *Eur J Endocrinol*. 2021 Feb 1:EJE-20-1309.R1. doi: 10.1530/EJE-20-1309.
- 126.** *Fleseriu M*, Molitch M, Dreval A, Biermasz NR, Gordon MB, Crosby RD, Ludlam WH, Haviv A, Gilgun-Sherki Y and Mathias SD (2021) Disease and Treatment-Related Burden in Patients With Acromegaly Who Are Biochemically Controlled on Injectable Somatostatin Receptor Ligands. *Front. Endocrinol.* 12:627711. doi: 10.3389/fendo.2021.627711
- 127.** K Ho, *M Fleseriu*, U Kaiser, R Salvatori, T Brue, M B Lopes, P Kunz, M Molitch, S A Camper, M Gadelha, L V Syro, E Laws, M Reincke, H Nishioka, A Grossman, A Barkan, F Casanueva, J Wass, A Mamelak, L Katznelson, A J van der Lely, S Radovick, M Bidlingmaier, M Boguszewski, J Bollerslev, A R Hoffman, N Oyesiku, G Raverot, A Ben-Shlomo, R Fowkes, I Shimon, H Fukuoka, A M Pereira, Y Greenman, A P Heaney, M Gurnell, G Johannsson, R Y Osamura, M Buchfelder, M Zatelli, M Korbonits, P Chanson, N Biermasz, D R Clemmons, N Karavitaki, M D

Bronstein, P Trainer, S Melmed, Pituitary Neoplasm Nomenclature Workshop: Does Adenoma Stand the Test of Time?, *Journal of the Endocrine Society*, Volume 5, Issue 3, March 2021, bvaa205, <https://doi.org/10.1210/jendso/bvaa205>

- 128.** *Fleseriu M* (2021) Pituitary Disorders and COVID-19, Reimagining Care; the Pandemic A Year and Counting Front. *Endocrinol.* | doi: 10.3389/fendo.2021.656025
- 129.** Hinojosa-Amaya JM, Varlamov EV, Yedinak CG, Cetas JS, McCartney S, Banskota S, *Fleseriu M* (2021). Echocardiographic findings in acromegaly: prevalence of concentric left ventricular remodeling in a large single-center cohort. *J Endocrinol Invest.* 2021 Apr 24. doi: 10.1007/s40618-021-01579-4
- 130.** Chiloiro S, Giampietro A, Visconti F, Rossi L, Donfrancesco F, *Fleseriu CM*, Mirra F, Pontecorvi A, Giustina A, *Fleseriu M*, De Marinis L, Bianchi A. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant. *Endocrine.* 2021 Apr 27. doi: 10.1007/s12020-021-02711-3
- 131.** Varlamov EV, Purnell JQ, *Fleseriu M* (2021). Glucocorticoid Receptor Antagonism as a New "Remedy" for Insulin Resistance - Not There Yet! *J Clin Endocrinol Metab.* 2021 Feb 28;dgab127. doi: 10.1210/clinem/dgab127
- 132.** Labadzhyan A, Nachtigall LB, *Fleseriu M*, Gordon MB, Molitch M, Kennedy L, Samson SL, Greenman Y, Biermasz N, Bolanowski M, Haviv A, Ludlam W, Patou G, Strasburger CJ. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results. *Pituitary.* 2021 Jun 25. doi: 10.1007/s11102-021-01163-2. Epub ahead of print. PMID: 34173129.
- 133.** Varlamov EV, Niculescu DA, Banskota S, Galoiu SA, Poiana C, *Fleseriu M* (2021). Clinical features and complications of acromegaly at diagnosis are not all the same: data from two large referral centers. *Endocr Connect.* 2021 Jun 1:EC-21-0035.R2. doi: 10.1530/EC-21-0035
- 134.** *M. Fleseriu*, R J. Auchus, R Pivonello, R. Salvatori, S. Zacharieva, Beverly MK Biller (2021) Levoketoconazole: a novel treatment for endogenous Cushing's syndrome, Expert Review of Endocrinology & Metabolism, DOI: [10.1080/17446651.2021.1945440](https://doi.org/10.1080/17446651.2021.1945440)
- 135.** Marcus HJ, Khan DZ, Borg A, Buchfelder M, Cetas JS, Collins JW, Dorward NL,

Fleseriu M, Gurnell M, Javadpour M, Jones PS, Koh CH, Layard Horsfall H, Mamelak AN, Mortini P, Muirhead W, Oyesiku NM, Schwartz TH, Sinha S, Stoyanov D, Syro LV, Tsermoulas G, Williams A, Winder MJ, Zada G, Laws ER (2021). Pituitary society expert Delphi consensus: operative workflow in endoscopic transsphenoidal pituitary adenoma resection. Pituitary. 2021 Jul 6:1–15.

- 136.** Tritos N, Fazeli P, McCormack A, Mallea-Gil S, Pineyro M, Christ-Crain M, Frara S, Labadzhyan A, Ioachimescu A, Shimon U, Takahashi I, Gurnell M, *Fleseriu M (2021)*, for the “Pituitary Society Delphi Collaborative Group”, Pituitary Society Delphi Survey: international perspective on endocrine management of patients undergoing transsphenoidal surgery for pituitary adenomas. *Pituitary*. 2021 Jul 10;
- 137.** Frara S, Loli P, Allora A, Santini C, di Filippo L, Mortini P, *Fleseriu M*, Giustina A (2021). COVID-19 and hypopituitarism. *Rev Endocr Metab Disord*. Aug 13:1–17. doi: 10.1007/s11154-021-09672-y
- 138.** *Fleseriu M*, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R (2021). More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. *Eur J Endocrinol*. Aug 27;185(4):525-538. doi: 10.1530/EJE-21-0239. PMID: 34342594.
- 139.** Han AJ, Varlamov EV, *Fleseriu M* (2021). Non-Functioning Pituitary Microadenomas, Should Imaging Interval be Extended? A Large Single-Center Cohort Study. *J Clin Endocrinol Metab*. 2021 Oct 14: dgab748. doi: 10.1210/clinem/dgab748. PMID: 34648635.
- 140.** Langlois F, Varlamov EV, *Fleseriu M* (2021). Hypophysitis, the Growing Spectrum of a Rare Pituitary Disease. *J Clin Endocrinol Metab*. 2021 Sep 16: dgab672. doi: 10.1210/clinem/dgab672. PMID: 34528683.
- 141.** *Maria Fleseriu*, Richard Auchus, Irina Bancos, Anat Ben-Shlomo, Jerome Bertherat, Nienke R Biermasz, Cesar L Boguszewski, Marcello D Bronstein, Michael Buchfelder, John D Carmichael, Felipe F Casanueva, Frederic Castinetti, Philippe Chanson, James Findling, Mônica Gadelha, Eliza B Geer, Andrea Giustina, Ashley Grossman, Mark Gurnell, Ken Ho, Adriana G Ioachimescu, Ursula B Kaiser, Niki Karavitaki, Laurence Katznelson, Daniel F Kelly, André Lacroix, Ann McCormack,

Shlomo Melmed, Mark Molitch, Pietro Mortini, John Newell-Price, Lynnette Nieman, Alberto M Pereira, Stephan Petersenn, Rosario Pivonello, Hershel Raff, Martin Reincke, Roberto Salvatori, Carla Scaroni, Ilan Shimon, Constantine A Stratakis, Brooke Swearingen, Antoine Tabarin, Yutaka Takahashi, Marily Theodoropoulou, Stylianos Tsagarakis, Elena Valassi, Elena V Varlamov, Greisa Vila, John Wass, Susan M Webb, Maria C Zatelli, Beverly M K Biller, (2021). Consensus on diagnosis and management of Cushing's disease: a guideline update, *Lancet Diabetes & Endocrinology*, DOI:[https://doi.org/10.1016/S2213-8587\(21\)00235-7](https://doi.org/10.1016/S2213-8587(21)00235-7)

Invited Publications

-Peer reviewed

142. *Maria Fleseriu* (1998) Updates in the Pathophysiology and Treatment of Hirsutism. *Acta Medica Transilvanica*, vol 1, nr. 1, pp 83-87.
143. *Maria Fleseriu* (1999) Recent Data on the Neuroendocrine Aspects of Human Obesity. *Acta Medica Transilvanica*, vol 2, nr 2, pp 27-33.
144. *Maria Fleseriu*, Lynn D Loriaux, William H Ludlam (2007) Second line treatment for Cushing's disease when initial pituitary surgery is unsuccessful. *Current Opinion in Endocrinology, Diabetes & Obesity*. 14(4): 323-328, August.
145. Liu JK*, *Fleseriu M**, Delashaw JB Jr, Ciric IS, Couldwell WT (2007) Treatment options for Cushing's disease after failed transsphenoidal surgery. *Neurosurg Focus*; 23(3):E8. *First author.
146. DL Loriaux, *Maria Fleseriu* (2009) Relative adrenal insufficiency. *Curr. Opin. Endocrinol Diabetes Obes.* Oct; 16(5): 392-400. Review.
147. *Maria Fleseriu* (2011), Investigational drugs may expand medical treatment of Cushing's syndrome, *Endocrine Today*; 6 (21):pp1.
148. John Carmichael, *Maria Fleseriu* (2012) "Mifepristone: is there a place in the

- treatment of Cushing's disease?" *Endocrine*. Aug; 44(1): 20-32.
149. *Maria Fleseriu* (2013), Combination treatment in acromegaly: hope for the non-responsive, *Current Opinion in Endocrinology, Diabetes & Obesity*, Volume 20, August 2013, Issue 3, pp. v-vi, 160-240.
 150. *Maria Fleseriu*, Shirley McCartney (2013), A New Era of Cushing Disease Therapeutics, *Acta Endo (Buc)* 9: 89-96.
 151. *Maria Fleseriu* (2014), Recent Advances in Medical Treatment of Cushing's disease, *F1000Prime Reports*, vol. 6, Mar 3; 6:18. doi: 10.12703/P6-18
 152. *Maria Fleseriu* (2014), Insight into cardiovascular risk factors in patients with acromegaly, *Endocrine*, editorial, Sep; 47(1): 1-2.
 153. *Maria Fleseriu* (2014), Cushing's syndrome, *British Medical Journal –Best Practice*.
 154. *Maria Fleseriu* (2014), Mifepristone in Cushing's disease: Long-term Results, *Medscape Medical News*.
 155. *Maria Fleseriu* (2015), Medical Therapy of Cushing's, new targets, new hope, *Endocrinology Clinics of North America*, 44(1): 51-70
 156. *Fleseriu M* (2015), Medical treatment of acromegaly in pregnancy highlights on new reports. *Endocrine*. Aug;49(3):577-9
 157. *Fleseriu M*, Petersenn S (2015), Cushing disease: Where do we stand, where are we heading? *Pituitary*. 18(2): 179-80.
 158. Ben-Shlomo A, *Fleseriu M* (2015), Updates and highlights in pituitary medicine. *Endocrinol Metab Clin North Am.*; 44(1)
 159. Cuevas-Ramos D, *Fleseriu M* (2016), Pasireotide: a novel treatment for patients with acromegaly, *Drug Design, Development and Therapy*, Volume 2016:10 Pages 227—239
 160. Ben-Shlomo A, *Fleseriu M* (2016), Pediatric Endocrinology, *Endocrinol Metab Clin North Am*. 2016 Jun; 45(2): xiii-xv
 161. Cuevas-Ramos D, DS Lim, *Fleseriu M* (2016), Update on medical treatment for Cushing's disease, *Clinical Diabetes and Endocrinology*, Sept
 162. Ben-Shlomo A, *Fleseriu M* (2016), Obesity, *Endocrinol Metab Clin North Am*. Sep;45(3):xiii-xv
 163. Ben-Shlomo A, *Fleseriu M* (2016), Diabetes, *Endocrinol Metab Clin North Am*.

Dec;46(4):xiii-xv

164. Langlois F, Dawn Lim, *Fleseriu M* (2017), Update on Adrenal Insufficiency: Diagnosis and Management in Pregnancy, *Current Opinion in Endocrinology and Diabetes*, 2017 Jun;24(3):184-192
165. Ben-Shlomo A, *Fleseriu M* (2017), Osteoporosis, *Endocrinol Metab Clin North Am*. 2017 Mar; 46(1):xiii-xv.
166. Ben-Shlomo A, *Fleseriu M* (2017), Updates in genetics of endocrine disorders, *Endocrinol Metab Clin North Am*. 2017 June; 47(1):xiii-xv.
167. Ben-Shlomo A, *Fleseriu M* (2017), Vitamin D Hormone: Where Do We Stand, Where Are We Heading? *Endocrinol Metab Clin North Am*. 2017 Dec;46(4):xiii-xv. doi: 10.1016/j.ecl.2017.09.002.
168. Varlamov E, McCartney S, *Fleseriu M* (2018), Growth hormone deficiency and replacement effect on adult bone mass: A clinical update, *Current Opinion in Endocrine and Metabolic Research* 2018, -:3:7–20
169. *Fleseriu M*, Karavitaki N (2018), Non-functioning pituitary adenomas, not all the same and certainly not boring!, *Pituitary*. Apr; 21(2):109-110
170. Hinojosa-Amaya JM, Cuevas-Ramos D, *Fleseriu M* (2019), Medical Management of Cushing's syndrome, Current and Emerging Treatments, *Drugs*. May 17. doi: 10.1007/s40265-019-01128-7
171. Gheorghiu ML, Negreanu F, *Fleseriu M* (2019), Updates in the Medical Treatment of Pituitary Adenomas, *Horm Metab Res*. 2019 Dec 20. doi: 10.1055/a-1066-4592
172. Varlamov E, Hinojosa-Amaya JM, *Fleseriu M* (2020), Magnetic resonance imaging in the management of prolactinomas; a review of the evidence, *Pituitary*, Feb;23(1):16-26
173. Fernandes S, Varlamov EV, McCartney S, Fleseriu M. A Novel Etiology of Hypophysitis: Immune Checkpoint Inhibitors. *Endocrinol Metab Clin North Am*. 2020;49(3):387-399. doi:10.1016/j.ecl.2020.05.002
174. C Capatina, J. M Hinojosa-Amaya, C Poiana, *M Fleseriu* (2020) Management of patients with persistent or recurrent Cushing's Disease after initial pituitary surgery, *Expert Review of Endocrinology & Metabolism*, DOI: [10.1080/17446651.2020.1802243](https://doi.org/10.1080/17446651.2020.1802243)

175. Langlois F, Suarez GM and *Fleseriu M* (2020) Updates in rare and not-so-rare complications of acromegaly: focus on respiratory function and quality of life in acromegaly *F1000Research*, 9, 791(<https://doi.org/10.12688/f1000research.22683.1>)
176. *Fleseriu M* (2020). Salivary Cortisol in the Diagnosis of Cushing Syndrome, Always More Than One!. *J Endocr Soc.*;4(10):bvaa109. Published 2020 Sep 9.
177. Capatana C, *Fleseriu M* (2021), Hypercoagulability in Cushing's syndrome, Current Opinion in Endocrinology, *Curr Opin Endocrinol Diabetes Obes.* 2021 Mar 17. doi: 10.1097/MED.0000000000000630
178. *Fleseriu M* (2021). Cushing's syndrome Part 1: Journey to Improving Diagnosis and Outcomes. *Best Pract Res Clin Endocrinol Metab.* Jan;35(1):101520 doi: 10.1016/j.beem.2021.101520
179. *Fleseriu M* (2021). Cushing's syndrome Part 2: Advances in Treatment and in Understanding Complications' Impact. *Best Pract Res Clin Endocrinol Metab.* 2021 Mar;35(2):101523. doi: 10.1016/j.beem.2021.101523
180. F Langlois, *M. Fleseriu* (2021), Pituitary incidentaloma in Internal Medicine Clinics of North America, SSN 0025-7125, <https://doi.org/10.1016/j.mcna.2021.05.015>

Chapters Books

181. *Maria Fleseriu* and I. Vintila, Chapter "Metabolism's Disorders" in "*Genetic Disorders and Birth Defects*", Sibiu, 1995.
182. *Maria Fleseriu* and I. Gh. Totoianu "*Endemic Goiter*" (three chapters), Publishing House TIPOTRIB Sibiu, 1997, ISBN 973-98325-7-1.
183. *Maria Fleseriu* and Mario Skugor, Hypothyroidism, Hyperthyroidism. *Disease management project*, The Cleveland Clinic, 2006.
184. Sehtu K Reddy and *Maria Fleseriu*, "Pituitary and Thyroid Disorders" chapter in "*Clinical Reproductive Medicine and Surgery*" Falcone T. and Hurd W., editors, Philadelphia, Elsevier Inc. 2007. ISBN: 0323033091.
185. Mario Skugor and *Maria Fleseriu*, "Hypothyroidism and Hyperthyroidism" chapter

in “*Current Clinical Medicine*”, Elsevier, 2009, ISBN 978-1-4160-4096-5.

186. Maria Fleseriu et al, “Acromegaly, an update”, *Pituitary Patient Resource Guide*, 5th edition
187. Maria Fleseriu et al, “Headache associated with pituitary tumors” in “*Evolving Therapies, Personalized Treatments, Improved Patient Outcomes*”, Editors Dr. Sylvia Asa and Dr. Shereen Ezzat.
188. Maria Fleseriu et al, Pituitary Disease in women in Pituitary Disorders: Diagnosis and Management, 1st edition, Wiley & Blackwell, Edited by: Edward R. Laws, Shereen Ezzat, Sylvia L. Asa, Linda M. Rio, Lorin Michel
189. Maria Fleseriu, Central Adrenal Insufficiency, *First Consult*, Elsevier, 2013.
190. Shirley McCartney, Chris Yedinak, Maria Fleseriu, Cushing’s syndrome, *Pituitary Patient Resource Guide*, 2013, PNA, Editor Dr Lewis Blevins.
191. Maria Fleseriu, Chapter 1, “Medical treatment of pituitary tumors” in *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, ISBN-10: 1588298159.
192. Chris Yedinak, Shirley McCartney, Maria Fleseriu, “Idiopathic granulomatous hypophysitis masquerading as a pituitary adenoma: do we have any reliable diagnostic criteria?” , *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, ISBN-10: 1588298159.
193. Chris Yedinak Jessica Brzana, Maria Fleseriu, “Cushing’s disease, what to do after failed surgery” *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, ISBN-10: 1588298159.
194. Jessica Brzana, Chris Yedinak, Maria Fleseriu, “Acromegaly, awareness is paramount for early diagnosis: highlights of diagnosis and treatment challenges”, *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, ISBN-10: 1588298159.
195. Liana Chicea, Maria Fleseriu, Cushing’s disease, Acromegaly and Autoimmune hypophysitis in “*Endocrinology – Challenging Cases*”, 2nd Edition, 2014, Editor Lucio Villar, ISBN-10, 978-85-277-2204-9.
196. Maria Fleseriu, ACTH- dependent hypercortisolemia in *Pituitary*, 1st edition, 2015, Editors Daniel Cuevas-Ramos, Miguel Ángel Gómez-Sámamo, Francisco J. Gómez-

Pérez, in press

197. Ciporen J, Cetas J, McCartney S, *Fleseriu M* "Cushing's disease, refining the definition of remission and recurrence", *HPA axis and Cushing's book*, 1st edition Springer 2016, Editor Eliza Geer
198. Daniel Cuevas-Ramos, *Maria Fleseriu*, "Medical treatment of Cushing's disease" in *Treatment of pituitary tumors*, Minerva Endocrinologica, 2016, Editor Ilan Shimon, Minerva Endocrinol. 2016 Sep;41(3):324-40.
199. *Maria Fleseriu*, "Management of Cushing's disease" in *Endocrinologia Clínica*, Grupo GEN, Brazil, editors Lucio Vilar, Maria Fleseriu, 2016
200. Dawn Shao Lim, *Maria Fleseriu*, "Management of Persistent Disease after Surgery in a Young Woman with Acromegaly" in *The Art of Neuroendocrinology: A Case-Based Approach to Medical Decision-Making*, Nova, Editor Lewis Blevins, 2016
201. Jeffrey Wagner, *Maria Fleseriu*, "Cushing's syndrome, what should we do while looking for the source? In *The Art of Neuroendocrinology: A Case-Based Approach to Medical Decision-Making*, Nova, Editor Lewis Blevins, 2016
202. Sarah Hopkins, *Maria Fleseriu*, "Medical Treatment of Cushing's Disease" in *Cushing's syndrome*, Elsevier, 2016, Editor Ed Laws
203. Fabienne Langlois, *Maria Fleseriu*, "Adrenal insufficiency" in *Conn's Current Therapy* 2017-2018, Elsevier
204. *Maria Fleseriu*, "Drugs and pituitary function" in *Pituitary*, 3rd edition, 2017, Elsevier, Editor Shlomo Melmed
205. *Maria Fleseriu*, "Pituitary function in systemic diseases" in *Pituitary*, 3rd edition, 2017, Elsevier, Editor Shlomo Melmed
206. Fabienne Langlois, *Maria Fleseriu*, "Adrenal insufficiency" in *Conn's Current Therapy* 2018-2019, Elsevier
207. F Langlois, E.V Varlamov, *M Fleseriu* Hypopituitarism in *Conn's Current Therapy* 2019-2020, Elsevier
208. Varlamov E, Liu W, McCartney S, Cetas J, *Fleseriu M*, "Primary medical therapy for acromegaly, ready for prime time?" In: Little A, Mooney M (eds) *Controversies in Skull Base Surgery*. 2019, Thieme, New York, pp 78-86
209. Dawn Lim, *Maria Fleseriu*, "Combination treatment in acromegaly", in Blevins L,

Aghi M (eds), *Acromegaly*, 2021, Springer

210. Greisa Vila, *Maria Fleseriu*, “Preconception management of female patients with hypopituitarism” in Samson S (ed) *Pituitary disease, from preconception to aging*, 2021, Springer
211. J.M. Hinojosa-Amaya, E.V. Varlamov, S.McCartney, “Pituitary magnetic resonance imaging use in the post-treatment follow-up of secreting pituitary adenomas” in *Pituitary Tumors, Comprehensive and Interdisciplinary Approach*, 2021
212. M. Fleseriu, “Pituitary Tumors Are More Frequent Than Previously Thought” in *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, 2021, Springer
213. Capatina C, Poiana C and Fleseriu M, “Dopamine Agonist-Induced Impulse Control Disorders” in *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, 2021, Springer
214. Stuti Fernandes, Elena V. Varlamov, Maria Fleseriu Abrupt weight gain, hypertension and severe hypokalemia in a young in *A Case-Based Guide to Clinical Endocrinology (Contemporary Endocrinology)*, Editor Terry Davies, 2021, Springer